Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life

Pediatric Infectious Disease Journal

Volumn 29, Issue 8, 2010, Pages 768-770

  Diez Domingo, Javier ^a,b   Planelles Cantarino, M Victoria ^b   Baldo Torrenti, Jose M ^b   Ubeda Sansano, Isabel ^b   Jubert Rosich, Angels ^b   Puig Barbera, Joan ^b   Gutierrez Gimeno, M Victoria ^a  

^a Centro Superior de Investigacion en Salud Publica CSISP   (Spain)

^b Vaccine Institute of Valencia (VIVA)   (Spain)

Author keywords

immunization; meningococcal vaccines; Neisseria meningitidis; secondary; serotype C

Indexed keywords

DIPHTHERIA TOXOID CRM197; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; TETANUS TOXOID; BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; MENINGOCOCCAL GROUP C POLYSACCHARIDE-TETANUS TOXOID CONJUGATE; SEROGROUP C MENINGOCOCCAL CONJUGATE VACCINE;

ANTIBODY RESPONSE; ARTICLE; BACTERICIDAL ACTIVITY; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; FOLLOW UP; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SEROLOGY; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; INFANT; MENINGOCOCCAL INFECTIONS; PROCEDURES; TIME; VACCINATION;

ANTIBODIES, BACTERIAL; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; TETANUS TOXOID; TIME FACTORS; VACCINATION;

EID: 77955174704     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181d9e653     Document Type: Article

References (10)

1. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365-367.
2. Larrauri A, Cano R, Garcia M, et al. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005;23:4097-4100.
3. Tejedor JC, Moro M, Merino JM, et al. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age. Pediatr Infect Dis J. 2008;27:579-588.
4. Diez Domingo J, Planelles Cantarino V, Baldó Torrentí J, et al. A randomized, multicentre, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months, as well as the importance of priming. Pediatr Infect Dis J. 2010;29:148-152.
5. de Voer RM, van der Klis FR, Engels CW, et al. Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults. Vaccine.
6. Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ. 2008;336:1487-1491.
7. Southern J, Crowley-Luke A, Borrow R, et al. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine. 2006;24:215-219.
8. Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis. 2001;183:160-163.
9. Snape MD, Kelly DF, Green B, et al. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J. 2005;24:128-131.
10. Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol. 2005;162:89-100.